Alyeska Investment Group
XERS icon

Alyeska Investment Group’s Xeris Biopharma Holdings XERS Stock Holding History

Alyeska Investment Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-300,000
Closed -$798K – 599
2020
Q2 		$798K Buy
+300,000
New +$1.04M 0.01% 412

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group's XERS Position: Q3 2020 in Review

Alyeska Investment Group sold out of Xeris Biopharma Holdings (XERS) in Q3 2020, closing a stake of 300,000 shares — an estimated $798K sold.

Alyeska Investment Group first reported a position in XERS in Q2 2020 and held it in 1 quarter. The position peaked at $798K in Q2 2020. 86 funds tracked by Wall St. Rank hold XERS as of Q3 2020.

  • Alyeska Investment Group reported no remaining Xeris Biopharma Holdings position as of Q3 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 300,000 Xeris Biopharma Holdings shares in Q3 2020, an estimated $798K.
  • Alyeska Investment Group first reported a position in Xeris Biopharma Holdings in Q2 2020 and held it in 1 quarter.
  • Alyeska Investment Group's Xeris Biopharma Holdings position peaked at $798K in Q2 2020.
  • 86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2020.

Based on Alyeska Investment Group's 13F filing for Q3 2020, filed 16 Nov 2020.